<DOC>
	<DOCNO>NCT01094340</DOCNO>
	<brief_summary>This 24-week , randomize , double-blind , placebo-controlled study effect thalidomide placebo CSF ( cerebral spinal fluid ) plasma biomarkers patient mild moderate Alzheimer 's disease . This study evaluate effect 24 week treatment Thalidomide plasma biomarkers .</brief_summary>
	<brief_title>Thalidomide Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>A lumbar puncture do treatment ( baseline ) , 24 week collect CSF quantification biomarkers . As exploratory effort , test effect thalidomide biomarkers plasma determine detectable change mirror change observe CSF .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Subjects must screen diagnosis Probable Alzheimer 's disease accord National Institute Neurological Communicative Disorders StrokeAlzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criterion . Subjects must MiniMental State Examination ( MMSE ) score 1226 Subject must live home . Must caregiver participate study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>